IMU

5.56%

5.7¢ imugene limited

Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-29

First 29 Last

Share
Profile

Follow
Stungun

449 Posts.

73

30/06/23

09:22

Post #: 68546797
Share

Originally posted by Watmighthavben: ↑

Her Vaxx has often been viewed as a comparable if not better drug than Roche's Herceptin, given not only its outstanding overall survival rates (OSR) but it's strong safety parameters. With peak sales of approximately $6 billion USD Herceptin may well have been worth close to $25 billion USD to the Roche pharmaceutical company. That's a value equivalent in excess of $5 per IMU share when taking Imugene's current market cap and shares on offer into consideration. Yes the HER 2 market is a more competitive space than when Herceptin first arrived and reached peak sales, but it shows how completely ridiculous the IMU share price is at these levels.

To think a Big Pharma, hedge fund or large Asian investor is not going to pay north of $5bn USD for a piece of the her Vaxx and B Cell pie is fanciful. It is no doubt looking like Merck, as they are in combination with Her Vaxx via the Keytruda route, but I wouldn't be ruling out Roche (in combination with PD1 Vaxx) or Pfizer either. Like PD1 Vaxx, which in my mind is an awesome drug trialling in one of the world's largest cancer markets (i.e., lung cancer), Her Vaxx is going to have significant interest as the medical world awakes to its huge combination potential. Low costs of manufacturing, little or no toxicity and the potential to treat a vast array of cancer indications in are all upside for the acquirer.

This time last year when the Her Vaxx overall survival rates were announced IMU was three times the price it is today. OSR results are even better now and Imugene's clinical trials are far more advanced than they were back then. This stock is due for serious rerate in July.

DYOR Seek investment advice as and when required Opinions only

Expand

Thanks again for your insights Ben. Truely appreciate your posts.

IMU Price at posting: 8.9¢ Sentiment: Buy Disclosure: Held
22 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

RCE

Recce's R327 found effective against E.coli during clinical trial

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 128 more messages in this thread...

First 29 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.7¢		Change 0.003(5.56%)		Mkt cap ! $417.2M

Open	High	Low	Value	Volume
5.5¢	5.8¢	5.2¢	$2.499M	45.00M

Buyers (Bids)

No.	Vol.	Price($)
2	1921794	5.6¢

Sellers (Offers)

Price($)	Vol.	No.
5.7¢	1368288	7

View Market Depth

No.	Vol.	Price($)
5	286362	0.055
9	2036888	0.054
16	2736044	0.053
20	1943436	0.052
23	3206056	0.051

Price($)	Vol.	No.
0.057	378902	2
0.058	1552127	7
0.059	837099	8
0.060	2176188	16
0.061	1163926	6

Last trade - 16.10pm 28/06/2024 (20 minute delay)

IMU (ASX) Chart

Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-29

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: HER-Vaxx induced antibodies correlated with tumour reduction, page-29

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Microcap Wrap: 5 explorers with news out today

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News